Epilepsy-related Brain Tumors Register
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03876093|
Recruitment Status : Recruiting
First Posted : March 15, 2019
Last Update Posted : March 15, 2019
Epilepsy is defined by a cerebral disorder characterized by a lasting predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological and social consequences of this affection. The definition of epilepsy requires the occurrence of at least one epileptic seizure. 1% of the population suffers from epilepsy. The most common causes are genetic and vascular, 10% of epileptic syndromes are caused by a tumor.
The incidence of brain tumors in people with epilepsy is approximately 4%. Among patients with brain tumor (s), the frequency of epilepsy is 30% or more depending on type of tumeur. 30-50% of brain tumors are revealed by an epileptic seizure and 10 to 30% of patients with brain tumor (s) will develop seizures during their evolution.
The main objective is to evaluate the frequency of epileptic seizures according to the type of brain tumor.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Epilepsy-related Brain Tumors Register|
|Actual Study Start Date :||October 1, 2018|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||June 30, 2024|
- number of epileptic seizures [ Time Frame: Day 1 ]number of epileptic seizures at the time of neurology consultation or hospitalization
- number of epileptic seizures [ Time Frame: until 10 years ]number of epileptic seizures at every visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03876093
|Contact: Roubeau Vincent, MDfirstname.lastname@example.org|
|Groupe Hospitalier Paris Saint-Joseph||Recruiting|
|Paris, France, 75014|
|Contact: Groupe Hospitalier P Saint-Joseph 144127038 email@example.com|
|Principal Investigator:||Roubeau Vincent, MD||Groupe Hospitalier Paris Saint Joseph|